472 related articles for article (PubMed ID: 29288305)
1. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
2. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
[TBL] [Abstract][Full Text] [Related]
3. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy.
Murata A; Amano N; Sato S; Tsuzura H; Tomishima K; Sato S; Matsumoto K; Shimada Y; Iijima K; Genda T
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192084
[TBL] [Abstract][Full Text] [Related]
4. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
[TBL] [Abstract][Full Text] [Related]
5. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
[TBL] [Abstract][Full Text] [Related]
6. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
[TBL] [Abstract][Full Text] [Related]
7. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.
Liu J; Hu HH; Lee MH; Korenaga M; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; Mizokami M; Chen CJ; Yang HI
Sci Rep; 2017 Oct; 7(1):14352. PubMed ID: 29085039
[TBL] [Abstract][Full Text] [Related]
8. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
[TBL] [Abstract][Full Text] [Related]
9. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
10. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
11. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
[TBL] [Abstract][Full Text] [Related]
12. Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy.
Yang SW; Kim GH; Chung JW; Sohn HR; Lee SS; Hong S; Chung SM; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2015 Jul; 30(7):1175-82. PubMed ID: 25707935
[TBL] [Abstract][Full Text] [Related]
13. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H; Nakagawa M; Nishimura-Sakurai Y; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Goto F; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Tojo N; Tohda S; Asahina Y; Watanabe M;
Hepatol Int; 2016 Nov; 10(6):956-964. PubMed ID: 27435935
[TBL] [Abstract][Full Text] [Related]
14. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Hosaka T; Suzuki F; Kobayashi M; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2010 Nov; 30(10):1461-70. PubMed ID: 20840396
[TBL] [Abstract][Full Text] [Related]
15. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
16. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
17. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
18. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
19. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
[TBL] [Abstract][Full Text] [Related]
20. Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Loglio A; Iavarone M; Viganò M; Orenti A; Facchetti F; Cortinovis I; Lunghi G; Ceriotti F; Occhipinti V; Rumi M; Sangiovanni A; Colombo M; Lampertico P
Liver Int; 2019 Oct; 39(10):1964-1974. PubMed ID: 31323159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
